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Abstract
Background Thyroidectomy is the typical treatment for pediatric thyroid carcinoma; total thyroidectomy is com-
monly performed. We aimed to report our experience at a single tertiary institution and to evaluate the risk factors for
recurrence, especially based on surgical extent, in pediatric patients with differentiated thyroid carcinoma (DTC).
Methods A data of 94 pediatric patients who underwent thyroid surgery for DTC from January 1982 to December
2012 at Yonsei University Hospital (Seoul, Korea) were reviewed. The clinicopathologic features and surgical
outcomes were retrospectively analyzed through complete chart reviews.
Results The mean age was 16.6 ± 3.0 (range, 5–19) years. Fourteen patients had recurrence. Tumor size [2 cm
(hazard ratio [HR], 14.241; p = 0.011) and positive lymph nodes (HR, 1.056; p = 0.039) were significant risk factors
for disease-free survival (DFS) in multivariate analysis. In Kaplan–Meier analysis, a statistically significant differ-
ence was noted in the DFS according to tumor size 2 cm (p\ 0.001). However, the DFS was not significantly
different between the bilateral total thyroidectomy (BTT) and less than BTT groups (p = 0.215).
Conclusions BTT remains the treatment of choice in pediatric patients with DTC. Lobectomy may be considered for
patients with limited disease, including those with tumor size \2 cm, no suspicious lymph nodes, intrathyroidal
lesion, and no multifocal disease.
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Introduction
Thyroid carcinoma is very rare during childhood and
accounts for 1.8% of all thyroid malignancies, according to
the surveillance, epidemiology, and end results program
[1]. Among thyroid carcinomas, differentiated thyroid
carcinoma (DTC) is the most common endocrine carci-
noma in pediatric patients, accounting for 90–95% of all
pediatric thyroid carcinomas [2, 3]. Papillary thyroid car-
cinoma (PTC) accounts for[90% of all cases of DTC, and
follicular thyroid carcinoma is a rare histological type
[4, 5].
Pediatric DTC can be differentiated from adult DTC
based on several characteristics. The disease is more
extensive, with more common extrathyroidal extension
(ETE) and a higher risk of recurrence, in pediatric patients
[6–8]. Several studies have reported that the incidence of
distant metastasis is up to 25% and that of lymph node
metastasis ranges from 40 to 80% [8–10]. Despite the more
aggressive disease features and higher risk of recurrence,
the long-term outcome has been reported to be better in
pediatric patients than in adult patients [11, 12].
Treatment of pediatric DTC generally involves surgery
and postoperative treatment, such as radioactive iodine
(RAI) therapy and thyroid-stimulating hormone suppres-
sion. Surgery is the main approach for treating DTC, and
the extent of surgery ranges from lobectomy to bilateral
total thyroidectomy (BTT). According to the American
Thyroid Association (ATA) management guidelines, the
treatment of choice for pediatric patients with DTC is
thyroidectomy, especially BTT [13]. BTT is preferred
because of the increased incidence of bilateral and multi-
focal disease, as well as an increased risk of recurrence
[6, 9, 14]. In addition, RAI therapy is administered and
thyroglobulin (Tg) serves as a tumor marker when BTT is
performed [14, 15]. However, the disadvantages of BTT
could lead to various complications, such as transient/
persistent postoperative hypoparathyroidism and recurrent
laryngeal nerve injury [16, 17]. Permanent hypoparathy-
roidism may develop in \2.5% of the patients, and per-
manent recurrent laryngeal nerve palsy may develop in
approximately 1% of the patients, even when the procedure
is performed by experienced surgeons [18, 19].
This retrospective study aimed to report our experience
at a single tertiary institution and to evaluate the risk fac-
tors for recurrence, especially based on the extent of sur-
gery, in pediatric patients with DTC.
Methods
Patients
The data of 110 pediatric (age B19 years) patients with
DTC who underwent thyroidectomy at Yonsei University
Hospital (Seoul, Korea) between January 1982 and
December 2012 were retrospectively reviewed. Sixteen
pediatric patients were excluded because they were lost to
follow-up. The data of 94 patients were completely ana-
lyzed by reviewing the medical charts and pathology
reports. Among them, 61 (64.9%) patients underwent BTT
and/or modified radical neck dissection (mRND) and 33
(35.1%) patients underwent less than BTT. The mean fol-
low-up duration was 148.6 ± 81.6 months (range,
60–452 months). This study was approved by the local
institutional review board (approval no. 4-2017-1099),
which waived the requirement for informed consent due to
the retrospective nature of this study.
Surgical treatment
Pediatric patients with DTC were followed up based on the
ATA management guidelines for children [13]. According
to the ATA guidelines, BTT is recommended for most
children owing to an increased incidence of bilaterality and
multifocal disease in this population. In long-term analysis,
BTT has been shown to decrease the risk of recurrence
[20]. However, for the study patients, lobectomy was per-
formed only when the disease was apparently limited, such
as for an intrathyroidal lesion or when bilaterality was not
observed on preoperative evaluation. Prophylactic central
compartment node dissection was regularly performed for
all pediatric patients. Therapeutic mRND was performed in
cases with clinically suspicious or pathologically con-
firmed N1b disease.
Postoperative management and follow-up
All pediatric patients were managed after surgical treat-
ment according to the ATA management guidelines for
children [13]. All patients took suppressive doses of
L-thyroxine and were regularly followed up with physical
examination, thyroid function testing, assessment of anti-
Tg antibody concentrations, and neck ultrasonography
every 3–6 months, and annually thereafter. RAI ablation
was performed at 6–8 weeks postoperatively, and whole-
body scans were performed at 5–7 days after RAI ablation
in patients who underwent BTT. If necessary, additional
diagnostic imaging, such as computed tomography, posi-
tron emission tomography/computed tomography, and/or
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RAI whole-body scanning were performed to confirm
recurrent disease.
Statistical analysis
All statistical analyses were performed with the SPSS
software package (SPSS version 23.0 for Windows; SPSS,
Chicago, IL, USA). Continuous variables are reported as
mean with standard deviation, and categorical variables are
reported as number with percentage. Student’s t-test, Chi-
square test, or Fisher’s exact test, if necessary, was used to
compare the two groups. To determine the optimal cutoff
value of the lymph node ratio (LNR), receiver operating
characteristic (ROC) curve analysis was performed. Uni-
variate and multivariate Cox regression analyses were
performed to validate the predictors of disease-free sur-
vival (DFS). Hazard ratios (HRs) with 95% confidence
intervals (CIs) were calculated. Kaplan–Meier survival
analysis with log-rank test was performed to compare the
DFS among the different groups. A statistically significant
difference was defined as p\ 0.05.
Results
Baseline clinicopathologic characteristics
Table 1 presents the baseline clinicopathologic character-
istics of the 94 total pediatric patients who underwent
thyroid surgery for DTC. The mean age of the patients was
16.6 years (range, 5–19 years). Six (6.4%) patients were
aged B10 years, and there were 84 (89.4%) female
patients. The mean tumor size was 2.1 cm (range,
0.3–9 cm), and most tumors (92.6%) were diagnosed as
PTC. Multifocality, bilaterality, and ETE of the disease
were diagnosed in 22 (23.4%), 14 (14.9%), and 34 (36.2%)
patients, respectively. The tumor-node-metastasis (TNM)
stage was classified based on the 8th edition of the
American Joint Committee on Cancer/Union for Interna-
tional Cancer Control TNM staging system. The distribu-
tion of patients according to each T stage was as follows:
stage 1, 42 patients (44.7%); stage 2, 17 patients (18.1%);
stage 3, 31 patients (33.0%); and stage 4, 4 patients (4.3%).
The number of patients diagnosed with N1a and N1b was
41 (43.6%) and 30 (31.9%), respectively. Only two patients
(2.1%) had distant metastasis in the lung at the time of the
thyroid carcinoma diagnosis. Fourteen (14.9%) patients
were diagnosed with recurrence after the initial treatment.
Comparison of baseline clinicopathologic
characteristics according to tumor size, age
and LNR
The patients were divided into the following two groups:
small tumor group (B2 cm, n = 50, 53.2%) and large
tumor group ([2 cm, n = 44, 46.8%). There were no sta-
tistically significant differences in age, proportion of
female patients, multifocality, and bilaterality between the
two groups. However, the large tumor group underwent a
significantly more extensive surgery than the small tumor
group (77.3% vs. 54.0%, p = 0.030). The large tumor
group presented a significantly higher ETE rate, number of
Table 1 Baseline clinicopathologic characteristics
Total 94 patients
Age (years) 16.6 ± 3.0 (range, 5–19)
B10 6 (6.4%)
[10 88 (93.5%)
Male: female 1: 8.4 (10: 84)








Less than BTT 33 (35.1%)
BTT and/or mRND 61 (64.9%)
Harvested LNs 21.0 ± 24.0













Follow up duration (months) 148.6 ± 81.6 (range, 60–452)
Data are expressed as the patient number (%) or mean ± SD
PTC papillary thyroid carcinoma, FTC follicular thyroid carcinoma,
ETE extrathyroidal extension, BTT bilateral total thyroidectomy,
mRND modified radical neck dissection, LN lymph node, T tumor,
N node, M metastasis
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harvested lymph nodes, and number of positive lymph
nodes than the small tumor group (p\ 0.001, p = 0.005,
and p = 0.012, respectively). On the basis of the T and N
stages, the large tumor group had a significantly higher
grade (p\ 0.001 and p = 0.030, respectively). The recur-
rence rates were also significantly higher in the large tumor
group than in the small tumor group (2.0% vs. 29.5%,
p\ 0.001; Table 2).
Table 3 shows the comparison of the baseline clinico-
pathologic characteristics according to age. The patients
were divided into the following two groups according to
age 17 years because the mean age of the study patients
was 16.6 years: younger pediatric group (B17 years,
n = 35, 37.2%) and older pediatric group ([17 years,
n = 59, 62.8%). There were no statistically significant
differences in the proportion of female patients, mean
tumor size, multifocality, bilaterality, T stage, and recur-
rence rate between the two groups. However, the younger
pediatric group underwent a significantly more extensive
surgery than the older pediatric group (82.9% vs. 54.2%,
p = 0.007). The younger pediatric group presented a sig-
nificantly higher ETE rate, number of harvested lymph
nodes, and number of positive lymph nodes than the older
pediatric group (p\ 0.026, p = 0.002, and p = 0.020,
respectively). On the basis of the N stage, the younger
pediatric group had a significantly higher grade
(p = 0.027).
The results of the comparison of the baseline clinical
characteristics according to the LNR are summarized in
Table 4. We evaluated the optimal cutoff value using the
LNR from the ROC curve analysis, and divided the patients
into the low LNR group (B0.4, n = 64, 68.1%) and the
high LNR group ([0.4, n = 30, 31.9%). There were no
significant differences between the two groups except for
the mean age, ETE, and N stage. The high LNR group
presented a significantly higher rate of ETE (53.3% vs.
28.1%). On the basis of the N stage, the high LNR group
had a significantly higher grade than the low LNR group
(p\ 0.001). However, there were no statistically signifi-
cant differences in the recurrence rate between the two
groups (10.9% vs. 23.3%, p = 0.131).
Table 2 Comparison of baseline clinicopathological characteristics according to tumor size (2 cm)
Tumor size B2 cm (n = 50) Tumor size[2 cm (n = 44) p value
Age (years) 16.9 ± 3.0 16.4 ± 3.0 0.426
Female 46 (92.0%) 38 (86.4%) 0.507
Extent of operation 0.030
Less than BTT 23 (46.0%) 10 (22.7%)
BTT and/or mRND 27 (54.0%) 34 (77.3%)
Tumor size (cm) 1.1 ± 0.5 3.2 ± 1.2 \0.001
Multifocality 11 (22.0%) 11 (25.0%) 0.809
Bilaterality 5 (10.0%) 9 (20.5%) 0.245
ETE 8 (16.0%) 26 (59.1%) \0.001
Harvested LNs 14.5 ± 19.2 28.3 ± 26.8 0.005
Positive LNs 4.4 ± 7.2 8.9 ± 9.5 0.012
T stage \0.001
T1 42 (84.0%) 0
T2 0 17 (38.6%)
T3 8 (16.0%) 23 (52.3%)
T4 0 4 (9.1%)
N stage 0.030
N0 14 (28.0%) 9 (20.5%)
N1a 26 (52.0%) 15 (34.1%)
N1b 10 (20.0%) 20 (45.4%)
Recurrence 1 (2.0%) 13 (29.5%) \0.001
Data are expressed as the patient number (%) or mean ± SD
A statistically significant difference was defined as p\ 0.05
BTT bilateral total thyroidectomy, mRND modified radical neck dissection, ETE extrathyroidal extension, LN lymph node, T tumor, N node
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BTT and less than BTT group comparisons
The results of the comparison of the baseline clinico-
pathologic characteristics between the BTT and less than
BTT groups are shown in Table 5. There were no statisti-
cally significant differences in the mean tumor size
between the two groups (2.2 ± 1.0 vs. 1.8 ± 1.8 cm,
p = 0.193). However, the proportion of male patients was
significantly higher in the BTT group than in the less than
BTT group (p = 0.013). The incidence of multifocality,
bilaterality, and ETE was also significantly higher in the
BTT group than in the less than BTT group (p = 0.021,
p = 0.002, and p = 0.002, respectively). On the basis of the
T stage, the less than BTT group had a significantly lower
grade and the BTT group had a significantly higher grade
(p = 0.002). With respect to the N stage, all patients in the
less than BTT group were diagnosed with N0 or N1a stage
disease, whereas N1b stage disease was diagnosed in 30
(49.2%) patients in the BTT group (p\ 0.001). Seven
(11.5%) patients in the BTT group and 7 (21.2%) patients
in the less than BTT group were diagnosed with
recurrence; however, this result was not statistically sig-
nificant (p = 0.234).
Recurrence
Table 6 presents the approximate recurrence patterns in the
patients included in this study. All patients diagnosed with
recurrent disease underwent surgical treatment. Most of the
patients in the BTT group, with the exception of patient no.
6, experienced recurrence at the contralateral central
compartment lymph nodes. Patient no. 6 developed recur-
rence at the ipsilateral level 3 area and underwent mRND.
In comparison, patients in the less than BTT group showed
different recurrence patterns, as follows: 5 patients were
confirmed to have had recurrence at the thyroid contralat-
eral to the operated side, and patient no. 4 had recurrence at
the ipsilateral surgery bed. Patient no. 1 developed recur-
rence bilaterally at levels 3 and 4. Patient no. 7 developed
recurrence at the ipsilateral level 4 area and underwent
mRND.
Table 3 Comparison of baseline clinicopathological characteristics according to age (17 years)
Age B17 years (n = 35) Age[17 years (n = 59) p value
Age (years) 13.7 ± 3.1 18.4 ± 0.8 \0.001
Female 29 (82.9%) 55 (93.2%) 0.166
Extent of operation 0.007
Less than BTT 6 (17.1%) 27 (45.8%)
BTT and/or mRND 29 (82.9%) 32 (54.2%)
Tumor size (cm) 2.3 ± 1.0 1.9 ± 1.5 0.225
Multifocality 9 (25.7%) 13 (22.0%) 0.802
Bilaterality 7 (20.0%) 7 (11.9%) 0.371
ETE 18 (51.4%) 16 (27.1%) 0.026
Harvested LNs 30.7 ± 29.9 15.2 ± 17.5 0.002
Positive LNs 9.2 ± 10.4 4.9 ± 6.9 0.020
T stage 0.059
T1 10 (28.6%) 32 (54.2%)
T2 7 (20.0%) 10 (17.0%)
T3 15 (42.9%) 16 (27.1%)
T4 3 (8.5%) 1 (1.7%)
N stage 0.027
N0 7 (20.0%) 16 (27.1%)
N1a 11 (31.4%) 30 (50.9%)
N1b 17 (48.6%) 13 (22.0%)
Recurrence 7 (20.0%) 7 (11.9%) 0.371
Data are expressed as the patient number (%) or mean ± SD
A statistically significant difference was defined as p\ 0.05
BTT bilateral total thyroidectomy, mRND modified radical neck dissection, ETE extrathyroidal extension, LN lymph node, T tumor, N node
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Univariate and multivariate analyses of the risk
factors for recurrence
Table 7 shows the results of the univariate and multivariate
Cox regression analyses for identifying the risk factors
associated with the DFS. In univariate analysis, tumor size
[2 cm (HR, 17.168; p = 0.006), ETE (HR, 3.443;
p = 0.027), higher T stage (T2: HR, 11.123 [p = 0.031];
T3: HR, 10.726 [p = 0.026]; T4: HR, 21.642 [p = 0.012]),
and positive lymph nodes (HR, 1.071; p = 0.005) were
found to be significant predictors of recurrence. Among the
various risk factors, tumor size[2 cm and positive lymph
nodes were identified as significant risk factors for the DFS
in multivariate analysis. Especially, the most significant
predictor of the DFS was tumor size[2 cm (HR, 14.241;
p = 0.011).
In Kaplan–Meier analysis, a statistically significant
difference was noted in the DFS between the large tumor
group and the small tumor group (log-rank p\ 0.001;
Fig. 1). Conversely, there was no statistically significant
difference in the DFS between the BTT group and the less
than BTT group (log-rank p = 0.215; Fig. 2).
Discussion
The incidence of DTC has significantly increased in the last
2 decades and has also steadily increased in pediatric
patients [2, 21–23]. DTC manifests more aggressive fea-
tures in pediatric patients than in adults; however, the
prognosis is better known in pediatric patients
[6–8, 12, 24]. Similar to that in the other studies, lymph
node metastasis was observed in 75.5% and ETE was
observed in 36.2% of the patients in our study [6–10, 25].
According to the ATA management guidelines for chil-
dren, BTT is recommended in pediatric patients with DTC
because of the possibility of recurrence owing to the more
extensive disease pathology in this population [13]. Other
studies have also reported that BTT can reduce the inci-
dence of recurrence compared with lobectomy [6, 9, 26].
However, BTT can cause various postoperative complica-
tions, although such complications are rare. The compli-
cations can include permanent hypoparathyroidism or
vocal cord palsy, which can be associated with serious
long-term problems [18, 19]. Although there is a general
Table 4 Comparison of baseline clinicopathological characteristics according to lymph node ratio (0.4)
LNR B0.4 (n = 64) LNR[0.4 (n = 30) p value
Age (years) 16.2 ± 3.4 17.5 ± 1.5 0.044
Female 55 (85.9%) 29 (96.7%) 0.161
Extent of operation 0.821
Less than TT 22 (34.4%) 11 (36.7%)
TT and/or mRND 42 (65.6%) 19 (63.3%)
Tumor size (cm) 2.0 ± 1.2 2.3 ± 1.7 0.317
Multifocality 12 (18.8%) 10 (33.3%) 0.128
Bilaterality 9 (14.1%) 5 (16.7%) 0.762
ETE 18 (28.1%) 16 (53.3%) 0.022
Harvested LNs 21.6 ± 25.3 19.5 ± 21.2 0.695
Positive LNs 4.8 ± 7.0 10.1 ± 10.6 0.005
T stage 0.061
T1 30 (46.9%) 12 (40.0%)
T2 15 (23.4%) 2 (6.7%)
T3 16 (25.0%) 15 (50.0%)
T4 3 (4.7%) 1 (3.3%)
N stage \0.001
N0 23 (35.9%) 0
N1a 20 (31.3%) 21 (70.0%)
N1b 21 (32.8%) 9 (30.0%)
Recurrence 7 (10.9%) 7 (23.3%) 0.131
Data are expressed as the patient number (%) or mean ± SD
A statistically significant difference was defined as p\ 0.05
LNR lymph node ratio, TT bilateral total thyroidectomy, mRND modified radical neck dissection, ETE extrathyroidal extension, LN lymph node,
T tumor, N node
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Table 5 Comparison of baseline clinicopathological characteristics according to surgical method
BTT and/or mRND (n = 61) Less than BTT (n = 33) p value
Age (years) 16.0 ± 3.3 17.7 ± 2.1 0.008
Female 51 (83.6%) 33 (100%) 0.013
Tumor size (cm) 2.2 ± 1.0 1.8 ± 1.8 0.193
Multifocality 19 (31.1%) 3 (9.1%) 0.021
Bilaterality 14 (23.0%) 0 0.002
ETE 29 (47.5%) 5 (15.2%) 0.002
Harvested LNs 27.5 ± 26.0 8.9 ± 13.0 \0.001
Positive LNs 8.5 ± 9.1 2.8 ± 6.3 0.002
T stage 0.002
T1 19 (31.1%) 23 (69.6%)
T2 12 (19.7%) 5 (15.2%)
T3 26 (42.6%) 5 (15.2%)
T4 4 (6.6%) 0
N stage \0.001
N0 8 (13.1%) 15 (45.5%)
N1a 23 (37.7%) 18 (54.5%)
N1b 30 (49.2%) 0
Recurrence 7 (11.5%) 7 (21.2%) 0.234
Data are expressed as the patient number (%) or mean ± SD
A statistically significant difference was defined as p\ 0.05
BTT bilateral total thyroidectomy, mRND modified radical neck dissection, ETE extrathyroidal extension, LN lymph node, T tumor, N node
Table 6 Recurrence patterns for the study population
Patients Age Sex Tumor size (cm) Recurrence site DFS (months)
BTT
1 18 Female 2.7 Contralateral level 6 LNs 15
2 15 Female 3 Contralateral level 6 LNs 11
3 15 Female 3.3 Contralateral level 6 LNs 103
4 5 Female 4.8 Contralateral level 6 LNs 92
5 15 Male 4 Contralateral level 6 LNs 70
6 15 Female 2.4 Ipsilateral level 3 LNs 52
7 17 Female 2.2 Contralateral level 6 LNs 39
Less than BTT
1 16 Female 2.8 Bilateral level 3,4 LNs 10
2 17 Female 4 Contralateral thyroid 71
3 18 Female 2.5 Contralateral thyroid 67
4 16 Female 3 Ipsilateral op bed 33
5 19 Female 2.3 Contralateral thyroid 142
6 19 Female 2.5 Contralateral thyroid 35
7 17 Female 0.8 Contralateral thyroid & ipsilateral Level 4 LNs 84
All patients who underwent BTT received radioactive iodine ablation therapy
DFS disease-free survival, BTT bilateral total thyroidectomy, LN lymph node
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consensus that surgery is the primary treatment for pedi-
atric DTC, the extent of surgery remains controversial [24].
The main issue is related to the impact of the extent of
surgery on recurrence and the potential associated risk of
complications. Those who favor BTT claim that the pro-
cedure is related to improved DFS without significant
complications when performed by experienced surgical
teams [26, 27]. However, lobectomy has been proposed to
have comparable surgical outcomes in selected patients and
is considerably safer than BTT [28].
In the present study, 7 (11.5%) and 7 (21.2%) patients in
the BTT and less than BTT groups, respectively, experi-
enced disease recurrence. There was a distinct pattern of
recurrence in both groups. In the BTT group, all patients,
except one patient, experienced recurrence in the con-
tralateral central compartment. In comparison, 5 of the 7
patients in the less than BTT group experienced recurrence
in the thyroid contralateral to the operated side. This is
probably due to an invisible multifocal disease on the
contralateral thyroid of the lesion at the time of DTC
diagnosis. One patient who underwent lobectomy needed a
reoperation within 1 month after surgery because of lateral
neck node metastasis. It is possible that the lateral neck
node metastasis was missed at the time of DTC diagnosis.
Thus, we excluded this patient from our study population.
In this study, 1 (2.0%) and 13 (29.5%) patients in the
small tumor and large tumor groups, respectively, experi-
enced disease recurrence after the initial treatment. The
recurrence rate was significantly higher in the large tumor
group than in the small tumor group (p\ 0.001), and it
was also statistically significant in the Kaplan–Meier
analysis (log-rank p\ 0.001). However, there was no
statistically significant difference according to a tumor size
of 1 cm (log rank p = 0.098). Byeon et al. reported that
there was no significant difference in the DFS between the
papillary thyroid microcarcinoma group and the PTC
[1 cm group [29]. Recently, the LNR has been suggested
as a significant prognostic factor in adult patients with PTC
[30]. Rubinstein et al. reported that the LNR may be a
useful predictor of recurrence in pediatric patients with
Table 7 Univariate and multivariate analysis for disease-free survival
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Tumor size
B2 cm Ref Ref
[2 cm 17.168 (2.245–131.307) 0.006 14.241 (1.847–109.828) 0.011
ETE 3.443 (1.154–10.277) 0.027
T stage
T1 Ref
T2 11.123 (1.241–99.686) 0.031
T3 10.726 (1.319–87.210) 0.026
T4 21.642 (1.962–238.774) 0.012
Positive LNs 1.071 (1.020–1.123) 0.005 1.056 (1.003–1.111) 0.039
Data are expressed as the hazard ratio (HR) and 95% confidence interval (CI)
A statistically significant difference was defined as p\ 0.05
ETE extrathyroidal extension, LN lymph node, T tumor
Fig. 1 Disease-free survival curves according to tumor size (2 cm)
(log-rank p\ 0.001)
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PTC [31]. ROC curve analysis was performed to determine
the optimal cutoff LNR of 0.4. However, there was no
statistically significant difference in the DFS between the
low LNR and high LNR groups (log-rank p = 0.096).
To determine the risk factors associated with the DFS,
we conducted univariate and multivariate Cox regression
analyses. Only two risk factors, tumor size [2 cm and
positive lymph nodes, were identified as significant risk
factors for the DFS (HR, 14.241; 95% CI, 1.847–109.828
[p = 0.011] and HR, 1.056; 95% CI, 1.003–1.111
[p = 0.039], respectively). Conversely, the extent of sur-
gery was not a risk factor for the DFS. The less than BTT
group showed a high HR; however, this result was not
statistically significant in the univariate analysis (HR,
2.171; 95% CI, 0.787–5.989; p = 0.134). Kaplan–Meier
analysis for the DFS showed no significant differences
between the BTT and lobectomy groups (log-rank
p = 0.215). In contrast to the results reported in other
studies, the extent of surgery did not affect recurrence in
this study, which may be due to differences in the patients’
ethnicity or the patient groups in this study [4, 20, 27, 32].
Demidchik et al. suggested that lobectomy is only
acceptable in limited diseases, such as small solitary
intrathyroidal lesions without evidence of neck lymph node
involvement [4]. Massimino et al. reported that the prog-
nosis was favorable even after recurrence and was not
related to the extent of surgery [33]. Therefore, we suggest
that lobectomy may be an alternative to BTT, but only for
patients with limited disease, such as those with tumor size
\2 cm, no suspicious lymph nodes, intrathyroidal lesion,
and no multifocal disease. However, the disadvantage of
lobectomy is that serum Tg for evaluation of postoperative
disease status and RAI remnant ablation cannot be used.
There are some limitations of this study. First, this study
was retrospective in nature. Second, there may have been a
selection bias because the data were collected at a single
tertiary institution and do not represent the entire patient
population. Third, the study population included only 94
pediatric patients with a relatively short follow-up period
(148.6 ± 81.6 months, range 60–452 months). Fourth, the
30-year data do not reflect the changes in the indication of
surgical extent during this period. Finally, 88 (93.5%)
patients were aged [10 years and only 6 (6.4%) patients
were aged \10 years; therefore, it is unlikely that the
results can be generalized to the entire pediatric population.
However, the strength of this study was the follow-up of
every patient and the use of a standardized laboratory and
imaging protocol at a single institution. Furthermore, to the
best of our knowledge, only a few studies have reported the
long-term prognosis of pediatric DTC.
Conclusions
According to the ATA management guidelines for chil-
dren, BTT remains the treatment of choice for pediatric
patients with DTC. Decision making regarding the surgical
approach and the extent of surgery should strike a balance
between the completeness of tumor removal and the quality
of life of the patients. The results of this study show that
comparable surgical outcomes may be achieved with
lobectomy, and lobectomy may, hence, be considered for
patients with limited disease, such as those with tumor size
\2 cm, no suspicious lymph nodes, intrathyroidal lesion,
and no multifocal disease. Further studies are required to
determine whether lobectomy is useful in clinical practice
for pediatric patients with DTC.
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